Azenta, Inc. (AZTA): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el panorama dinámico de la innovación científica, Azenta, Inc. (AZTA) emerge como una potencia de precisión tecnológica, uniendo estratégicamente los complejos mundos de las ciencias de la vida y las tecnologías de semiconductores. Con un intrincado modelo de negocio que se une a la investigación de vanguardia, la fabricación avanzada y las soluciones especializadas, Azenta transforma los desafíos científicos en oportunidades innovadoras en dominios farmacéuticos, biotecnología y de investigación. Su enfoque único combina sofisticados sistemas de almacenamiento criogénico, equipos de alta precisión y un profundo compromiso con el avance tecnológico que los distingue en un mercado global en rápida evolución.

Azenta, Inc. (AZTA) - Modelo de negocios: asociaciones clave

Colaboraciones estratégicas con instituciones de investigación de ciencias de la vida

Azenta, Inc. mantiene asociaciones estratégicas con las siguientes instituciones de investigación:

Institución de investigación	Enfoque de asociación	Año establecido
Escuela de Medicina de Harvard	Tecnologías avanzadas de bioprocesamiento	2022
Instituto MIT Whitehead	Soluciones de gestión de muestras genómicas	2021

Asociaciones con compañías farmacéuticas y de biotecnología

Las asociaciones clave farmacéuticas y biotecnológicas incluyen:

• Pfizer Inc. - Gestión de muestras colaborativas y logística
• Terapéutica Moderna - Soluciones avanzadas de biorepository
• Bristol Myers Squibb - Tecnologías de cadena fría de precisión

Relaciones de proveedores con fabricantes avanzados de materiales y equipos

Las relaciones críticas de los proveedores abarcan:

Proveedor	Categoría de suministro	Valor anual del contrato
Thermo Fisher Scientific	Equipo de laboratorio	$ 12.5 millones
Corning Incorporated	Materiales avanzados	$ 8.3 millones

Alianzas con centros de investigación académicos y universidades

Asociaciones de investigación académica significativas:

• Universidad de Stanford - Colaboración de investigación de bioingeniería
• Universidad Johns Hopkins - Gestión de muestras de medicina de precisión
• Universidad de California, San Francisco - Desarrollo de tecnología genómica

Azenta, Inc. (AZTA) - Modelo de negocios: actividades clave

Diseñar y fabricar equipos de ciencias de la vida y semiconductores

En el año fiscal 2023, Azenta reportó ingresos por ventas de equipos de $ 340.7 millones, con un enfoque en procesos de fabricación especializados.

Categoría de equipo	Volumen de producción anual	Ubicación de fabricación
Equipo de ciencias de la vida	1.200 unidades	Woburn, MA y Shanghai, China
Equipo semiconductor	850 unidades	Billerica, MA

Soluciones de manejo y almacenamiento de muestras criogénicas

Azenta opera 8 instalaciones globales de biorepository con una capacidad de almacenamiento total de más de 500 millones de muestras biológicas.

• Sistemas de almacenamiento criogénico desplegados en 42 países
• Ingresos anuales de servicios de gestión de muestras: $ 127.5 millones
• Más de 3.500 instituciones de investigación y compañías farmacéuticas atendidas

Investigación y desarrollo de tecnologías avanzadas

La inversión de I + D para el año fiscal 2023 fue de $ 62.4 millones, lo que representa el 11.6% de los ingresos totales de la compañía.

Área de enfoque de I + D	Solicitudes de patentes	Proyectos de investigación activa
Tecnologías criogénicas	23	12
Procesamiento de semiconductores	18	9

Procesos de ingeniería y fabricación de precisión

Tolerancia de precisión de fabricación: ± 0.001 mm en los componentes críticos del equipo.

• ISO 9001: 2015 Instalaciones de fabricación certificadas
• Tiempo promedio del ciclo de fabricación: 6-8 semanas
• Tasa de rechazo de control de calidad: menos del 0.5%

Servicios globales de ventas y atención al cliente

Cobertura de ventas global en 6 continentes con 247 personal dedicado de ventas y soporte.

Región	Representantes de ventas	Horas de atención al cliente anual
América del norte	98	42,500
Europa	67	29,300
Asia-Pacífico	82	36,800

Azenta, Inc. (AZTA) - Modelo de negocios: recursos clave

Ingeniería especializada y experiencia técnica

Azenta, Inc. mantiene un fuerza laboral técnica altamente especializada Con la siguiente composición:

Categoría de empleado	Número de empleados
Personal total de I + D	387
Científicos a nivel de doctorado	129
Especialistas en ingeniería	258

Instalaciones de fabricación avanzadas

Azenta opera múltiples instalaciones de fabricación con las siguientes especificaciones:

• Ubicaciones de fabricación total: 6
• Regiones de fabricación primaria: Estados Unidos, China, Singapur
• Total de fabricación de pies cuadrados: 275,000 pies cuadrados

Tecnologías patentadas

Categoría de tecnología	Número de tecnologías propietarias
Tecnologías de almacenamiento criogénico	17
Tecnologías de equipos de semiconductores	23
Tecnologías de automatización de ciencias de la vida	12

Cartera de propiedades intelectuales

Los activos de propiedad intelectual de Azenta incluyen:

• Patentes activas totales: 142
• Aplicaciones de patentes pendientes: 38
• Familias de patentes: 56

Fuerza laboral hábil

Composición de la fuerza laboral	Número de empleados
Total de empleados	1,643
Titulares de grado avanzado	412
Especialistas técnicos	987

Azenta, Inc. (AZTA) - Modelo de negocio: propuestas de valor

Equipo científico de alta precisión para investigaciones y aplicaciones clínicas

Azenta ofrece equipos científicos con las siguientes especificaciones:

Tipo de equipo	Nivel de precisión	Segmento de mercado
Sistemas de almacenamiento criogénico	± 0.1 ° C precisión	Biorepositorio
Plataformas de gestión de muestras	99.9% Fiabilidad de seguimiento	Laboratorios de investigación
Herramientas de fabricación de semiconductores	Precisión a nivel nanométrico	Fabricación de alta tecnología

Soluciones de gestión de muestras innovadoras para ciencias de la vida

Las soluciones de gestión de muestras de Azenta incluyen:

• Sistemas de seguimiento de muestras automatizados
• Infraestructura de almacenamiento criogénico
• Plataformas de gestión de muestras de extremo a extremo

Tecnologías avanzadas de fabricación de semiconductores

Ofertas de tecnología de semiconductores:

Tecnología	Métrico de rendimiento	Aplicación de mercado
Sistemas de manejo de obleas	Compatibilidad de la oblea de 300 mm	Producción de semiconductores
Herramientas de alineación de precisión	Posicionamiento submicrón	Fabricación avanzada de chips

Sistemas de almacenamiento criogénico confiables y escalables

Capacidades de almacenamiento criogénico:

• Capacidad de almacenamiento: hasta 10 millones de muestras biológicas
• Rango de temperatura: -190 ° C a +37 ° C
• Tasa de conservación de integridad de muestra: 99.99%

Soluciones tecnológicas de vanguardia para desafíos científicos complejos

Métricas de solución tecnológica:

Categoría de soluciones	Capacidad tecnológica	Impacto del mercado
Automatización de ciencias de la vida	Gestión de muestras impulsada por IA	Mejora de la eficiencia de la investigación
Procesamiento de semiconductores	Manejo avanzado de material	Mejora de la precisión de fabricación

Azenta, Inc. (AZTA) - Modelo de negocios: relaciones con los clientes

Soporte de ventas directo y consulta técnica

Azenta brinda soporte de ventas directas a través de un equipo dedicado de 87 profesionales de ventas a partir del cuarto trimestre de 2023. La compañía reportó $ 524.7 millones en ingresos totales para el año fiscal 2023, con servicios de consulta técnica especializada integrados en múltiples segmentos comerciales.

Métrica de soporte al cliente	2023 datos
Representantes de ventas totales	87
Tiempo promedio de interacción con el cliente	2.3 horas por consulta
Tiempo de respuesta de soporte técnico	4.1 horas

Programas continuos de capacitación y educación del cliente

Azenta ofrece programas integrales de capacitación en los mercados de ciencias de la vida y equipos de semiconductores.

• Sesiones de capacitación anual: 42 talleres
• Módulos de capacitación en línea: 26 cursos digitales
• Participantes de capacitación certificada: 1.284 en 2023

Servicio personalizado para investigaciones e clientes industriales

La compañía atiende a 1.356 instituciones de investigación y clientes industriales con Paquetes de soluciones personalizadas.

Segmento de clientes	Número de clientes	Nivel de personalización
Instituciones de investigación	782	Alto
Clientes industriales	574	Medio a alto

Enfoque de asociación a largo plazo

Azenta mantiene una tasa promedio de retención de clientes del 89.6% en sus segmentos comerciales, con 73 clientes que tienen asociaciones superiores a 10 años.

Servicios técnicos y de mantenimiento receptivos

La infraestructura de soporte técnico incluye 132 ingenieros de soporte dedicados con cobertura global.

• Centros de apoyo global: 7 ubicaciones
• Disponibilidad de soporte técnico 24/7
• Tiempo de actividad promedio del equipo: 97.3%

Métrico de soporte	Actuación
Ingenieros de soporte total	132
Centros de apoyo global	7
Interacciones de soporte anual	4,672

Azenta, Inc. (AZTA) - Modelo de negocios: canales

Equipo de ventas directas

A partir de 2024, Azenta mantiene una fuerza de ventas directa dedicada de aproximadamente 215 profesionales de ventas en los mercados globales. El equipo de ventas se centra en las industrias de ciencias de la vida, semiconductores e materiales avanzados.

Región de ventas	Número de representantes de ventas
América del norte	95
Europa	65
Asia-Pacífico	55

Plataformas de comercio electrónico en línea

Azenta opera múltiples canales de ventas digitales con un volumen anual de transacciones en línea de $ 87.3 millones en 2023.

• Sitio web de la compañía (portal de ventas directas)
• Mercados de equipos científicos especializados
• Plataformas de adquisición digital

Conferencias científicas y ferias comerciales

Azenta participa en 42 conferencias internacionales científicas y tecnológicas anualmente, con un gasto de marketing estimado de $ 2.4 millones.

Redes de distribuidores

La compañía mantiene asociaciones con 87 distribuidores de equipos científicos globales en 23 países.

Región	Número de distribuidores
América del norte	28
Europa	32
Asia-Pacífico	27

Marketing digital y canales de comunicación técnica

Azenta aprovecha múltiples plataformas de comunicación digital con las siguientes métricas de participación:

• Seguidores de LinkedIn: 45,670
• Seguidores de Twitter: 22,340
• Asistentes técnicos de seminarios web (2023): 3.850
• Presupuesto anual de marketing digital: $ 1.7 millones

Azenta, Inc. (AZTA) - Modelo de negocios: segmentos de clientes

Organizaciones de investigación farmacéutica

Azenta atiende a organizaciones de investigación farmacéutica con soluciones críticas de ciencias de la vida. A partir de 2023, el mercado global de investigación farmacéutica se valoró en $ 179.4 mil millones.

Tipo de cliente	Tamaño estimado del mercado	Tasa de penetración
Top 20 compañías farmacéuticas	$ 98.6 mil millones	54.9%
Organizaciones de investigación farmacéutica de tamaño mediano	$ 52.3 mil millones	29.1%

Compañías de biotecnología

Las compañías de biotecnología representan un segmento significativo de clientes para las tecnologías de la vida de Azenta.

• Tamaño del mercado global de biotecnología en 2023: $ 627.2 mil millones
• Número de compañías de biotecnología activa en todo el mundo: 8,442
• Gasto estimado de I + D: $ 186.3 mil millones anualmente

Instituciones de investigación académica y gubernamental

Azenta ofrece equipos y servicios especializados a instituciones de investigación.

Tipo de institución	Número de clientes potenciales	Presupuesto de investigación anual
Las 100 mejores universidades de investigación	100	$ 68.4 mil millones
Laboratorios de investigación gubernamentales	237	$ 45.7 mil millones

Empresas de fabricación de semiconductores

La fabricación de semiconductores representa un segmento de clientes en crecimiento para Azenta.

• Tamaño del mercado global de semiconductores en 2023: $ 573.4 mil millones
• Número de fabricantes de semiconductores activos: 332
• Gasto estimado de equipos de capital: $ 89.6 mil millones

Laboratorios de atención médica y clínica

Los laboratorios clínicos representan un segmento crítico de clientes para las soluciones de diagnóstico de Azenta.

Tipo de laboratorio	Número total	Volumen de prueba anual
Laboratorios de diagnóstico clínico	6,773	8.2 mil millones de pruebas anualmente
Laboratorios hospitalarios	5,534	4.7 mil millones de pruebas anualmente

Azenta, Inc. (AZTA) - Modelo de negocio: Estructura de costos

Inversiones de investigación y desarrollo

Para el año fiscal 2023, Azenta, Inc. reportó gastos de I + D de $ 91.4 millones, lo que representa el 13.4% de los ingresos totales.

Año fiscal	Gastos de I + D	Porcentaje de ingresos
2023	$ 91.4 millones	13.4%
2022	$ 83.2 millones	12.9%

Gastos de fabricación y producción

Los costos totales de fabricación para Azenta en 2023 fueron de $ 237.6 millones, con un desglose clave de la siguiente manera:

• Costos laborales directos: $ 68.3 millones
• Gastos de materia prima: $ 112.5 millones
• Sobrecoss de fabricación: $ 56.8 millones

Operaciones globales de ventas y marketing

Los gastos de ventas y marketing para Azenta en el año fiscal 2023 totalizaron $ 129.7 millones.

Región geográfica	Gasto de marketing
América del norte	$ 62.4 millones
Europa	$ 37.2 millones
Asia-Pacífico	$ 30.1 millones

Mantenimiento de la infraestructura tecnológica

Los costos de mantenimiento de tecnología e infraestructura para 2023 fueron de $ 45.6 millones, que incluyen:

• Actualizaciones de sistemas de TI: $ 22.3 millones
• Inversiones de ciberseguridad: $ 12.5 millones
• Infraestructura en la nube: $ 10.8 millones

Adquisición y retención de talentos

Los recursos humanos y los gastos relacionados con el talento en 2023 ascendieron a $ 96.2 millones.

Categoría de gastos	Cantidad
Salarios y salarios	$ 76.5 millones
Beneficios para empleados	$ 15.3 millones
Reclutamiento y capacitación	$ 4.4 millones

Azenta, Inc. (AZTA) - Modelo de negocios: flujos de ingresos

Venta de equipos en el sector de ciencias de la vida

Para el año fiscal 2023, Azenta informó ventas de equipos de ciencias de la vida de $ 281.4 millones.

Categoría de productos	Ingresos ($ M)	Porcentaje de total
Sistemas de gestión de muestras automatizados	156.7	55.7%
Equipo de investigación genómica	124.6	44.3%

Soluciones de equipos de semiconductores

Las soluciones de equipos de semiconductores generaron $ 202.3 millones en ingresos para el año fiscal 2023.

Segmento de semiconductores	Ingresos ($ M)
Equipo de embalaje avanzado	112.5
Soluciones de prueba de semiconductores	89.8

Ingresos del sistema de almacenamiento de muestras criogénicas

Los sistemas de almacenamiento criogénico contribuyeron con $ 97.6 millones a los ingresos totales de Azenta en 2023.

• Soluciones de almacenamiento de biorepository: $ 62.3 millones
• Investigación de sistemas criogénicos institucionales: $ 35.3 millones

Contratos continuos de mantenimiento y servicio

Los contratos de servicio y mantenimiento generaron $ 73.8 millones en ingresos recurrentes para el año fiscal 2023.

Tipo de servicio	Valor del contrato anual ($ M)
Mantenimiento del equipo	48.5
Contratos de soporte técnico	25.3

Servicios de licencias y consultoría de tecnología

Los servicios de licencias y consultoría de tecnología representaron $ 41.2 millones en ingresos de 2023.

• Licencias de propiedad intelectual: $ 24.7 millones
• Servicios de consultoría: $ 16.5 millones

Ingresos anuales totales (2023): $ 696.3 millones

Azenta, Inc. (AZTA) - Canvas Business Model: Value Propositions

You're looking at the core reasons why pharmaceutical and biotech clients choose Azenta, Inc. for their critical research infrastructure. It's about de-risking their most valuable assets-their biological samples-and speeding up their R&D timelines. The numbers show where the business is focused.

Flawless sample integrity via automated cold-chain management.

This value proposition is anchored in the Sample Management Solutions (SMS) segment, which provides the physical and logistical backbone for sample preservation. The focus here is on reliability at scale, which is essential for multi-year clinical trials and biobanking efforts. The company's ability to maintain viability across ultra-low temperatures is non-negotiable for customers.

The financial contribution from this area for the full fiscal year 2025 was substantial:

Metric	Amount/Value
Full Year Fiscal 2025 SMS Revenue	$325 million
Q3 Fiscal 2025 SMS Revenue	$78 million
Q4 Fiscal 2025 SMS Revenue	$86 million

The Q3 2025 revenue for SMS was down 4% year-over-year, but Q4 saw a rebound with 2% reported growth, showing the lumpy nature of capital equipment sales like Automated Stores.

Accelerating drug discovery with high-throughput multiomics services.

The Multiomics segment is the growth engine, providing the analytical horsepower needed to turn stored samples into actionable data. This includes Next Generation Sequencing (NGS), which has been a consistent performer.

• NGS volume growth was at double-digit rates in Q2 2025.
• NGS pricing showed stabilization for the 4th consecutive quarter as of Q2 2025.
• Q3 Fiscal 2025 Multiomics Revenue was $66 million, up 4% year-over-year.
• Full Year Fiscal 2025 Multiomics Revenue was $269 million, up 6% year-over-year.

This segment's performance is key to the overall organic growth trajectory. For the full year 2025, Azenta, Inc.'s total organic revenue grew 3%.

End-to-end sample lifecycle management for complex therapies.

This value is the sum of both segments, supported by a strong balance sheet to ensure continuity of service, which is critical when managing samples for advanced cell and gene therapies. The company ended fiscal year 2025 with a total balance of cash, cash equivalents, and marketable securities of $546 million.

The overall financial results for the full fiscal year 2025 reflect this integrated approach:

• Full Year Fiscal 2025 Total Revenue: $594 million.
• Full Year Fiscal 2025 Adjusted EBITDA Margin: 11.2%, an improvement of 310 basis points year-over-year.
• Full Year Fiscal 2025 Non-GAAP Diluted EPS: $0.51.

The margin expansion, up 310 basis points for the year, shows the value of operational efficiencies being realized across the entire lifecycle management process.

Reduced time and cost to lead candidates in gene therapy.

Azenta, Inc. directly addresses the timeline and safety concerns in gene therapy development through strategic integrations. For instance, a partnership launched in May 2025 integrates their sequencing capabilities with Form Bio's computational solutions to provide AAV Genome Integrity Characterization using their LAAVA software.

This collaboration is designed to streamline lead candidate selection by providing data-driven insights into AAV capsid contents, aiming to enhance therapeutic safety and manufacturability, which directly translates to reduced development timelines and costs for gene therapy developers.

Enterprise-wide sample intelligence software and informatics.

The informatics layer, which includes software like Freezer Pro and Limfinity, transforms raw sample data into intelligence. This software underpins the reliability of the entire cold-chain service, ensuring data integrity matches sample integrity. While specific revenue for informatics is bundled, the focus on operational improvements across the board supports this value.

The company's commitment to operational excellence is evident in its profitability metrics, which are a direct result of better system utilization and cost execution:

Metric (Continuing Operations)	Q3 Fiscal 2025	Q4 Fiscal 2025
Adjusted EBITDA Margin	12.3%	13%
Non-GAAP Diluted EPS	$0.19	$0.21

Finance: draft 13-week cash view by Friday.

Azenta, Inc. (AZTA) - Canvas Business Model: Customer Relationships

You're looking at how Azenta, Inc. (AZTA) structures its interactions across its diverse product and service offerings as of late 2025. The approach is definitely segmented based on the value and complexity of the offering.

For high-value systems, like the Automated Stores and Cryogenic Systems, Azenta, Inc. relies on a dedicated direct sales force. This team manages the complex sales cycle for these capital equipment and the associated storage services. Management noted in their Q4 2025 update that they took decisive steps to reshape the commercial organization, including an expanded field presence, to sharpen go-to-market targeting for fiscal 2025.

The Sample Repository Services (SRS), a key part of the Sample Management Solutions (SMS) segment, necessitates consultative, long-term relationships. These services are foundational to the trust required for long-term sample custody. The revenue performance of this segment, which includes SRS, shows its scale:

Period Ended	Sample Management Solutions Revenue (Millions USD)	Year-over-Year Change
March 31, 2025 (Q2 FY25)	$80	8% increase
June 30, 2025 (Q3 FY25)	$78	4% decrease
September 30, 2025 (Q4 FY25)	$86	2% increase

For consumables and standard services, the relationship leans toward self-service and e-commerce channels. These are the more transactional elements of the business. The growth in these areas, specifically for Consumables and Instruments, was noted as a meaningful contributor to the Q4 2025 results.

Support for the installed base of systems is managed through technical support and service contracts. This ensures uptime and continued use of their hardware and software platforms, such as Freezer Pro and Limfinity. The SMS segment also reports revenue from Product Services, which falls under this relationship type.

Azenta, Inc. maintains definitely collaborative relationships with top pharma, as they provide services to the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. This focus is critical, as the company's overall fiscal year 2025 revenue was $593.8 million, with 39% of that revenue generated outside the United States in fiscal year 2025, showing a growing international footprint with these key customers.

• The company ended the fiscal year 2025 with $546 million in cash, cash equivalents, and marketable securities.
• The debt-to-equity ratio stood at a low 0.03.
• The overall business achieved an Adjusted EBITDA Margin of 11.2% for the full fiscal year 2025.

Finance: review the Q1 2026 sales pipeline against the 3% to 5% organic growth guidance for the full year 2026 by end of January.

Azenta, Inc. (AZTA) - Canvas Business Model: Channels

You're looking at how Azenta, Inc. (AZTA) gets its Sample Management Solutions and Multiomics services into the hands of pharmaceutical and biotech clients as of late 2025. The channels reflect a hybrid approach, mixing direct engagement for high-value services with broader distribution for core products.

The direct sales force targets the two core continuing operations segments. For the third quarter of fiscal year 2025, the Sample Management Solutions segment generated $78 million in revenue, while the Multiomics segment brought in $66 million. The direct team is essential for selling complex, automated cold-chain infrastructure and high-throughput genomic services.

For core products, Azenta, Inc. relies on a trusted network of third-party distributors globally. While the exact number of partners isn't public, this channel helps extend reach for products like consumables and instruments, which contributed to the Sample Management Solutions revenue decline of 4% year-over-year in Q3 fiscal 2025.

The company-owned biorepository and service centers form a critical physical channel, ensuring sample integrity and local access. As of the June 30, 2025, balance sheet date, Azenta, Inc. maintained a cash and liquidity balance of $565 million, supporting this global footprint. The new biorepository in Greater Boston, for instance, is a 40,000 square foot facility.

Here is a look at the known physical channel locations supporting their operations:

Region	City/Site	Type of Facility Mentioned
North America	Burlington, MA	Corporate Headquarters
North America	Indianapolis, IN	Flagship Biorepository
North America	Waltham, MA	Multiomics Location
North America	Research Triangle Park, NC	Laboratory/Facility
North America	Seattle, WA	Laboratory/Facility
Europe	Leipzig, Germany	Laboratory/Facility
Europe	Oxford, United Kingdom	Laboratory/Facility

Investor relations and webcasts serve as the direct channel to the financial community. Management is focused on margin expansion, projecting 300 basis points of Adjusted EBITDA margin expansion for the full fiscal year 2025.

• Azenta Life Sciences Investor Day was scheduled for Wednesday, December 10, 2025, with the webcast presentation starting at 1:00 PM ET.
• The Q4 and Full Year Fiscal 2025 Earnings Conference Call and Webcast was scheduled for Friday, November 21, 2025, at 8:30 AM ET.
• The company's Market Capitalization as of November 21, 2025, was reported at $1.38 billion.

Digital platforms are key for the Multiomics business, which includes the GENEWIZ brand. GENEWIZ from Azenta Life Sciences provides services like Next Generation Sequencing and Gene Synthesis. While the platform facilitates ordering and payment, specific digital ordering volume or user statistics for fiscal 2025 aren't reported.

The digital channel is reinforced through strategic integrations, such as the partnership announced in May 2025 with Form Bio to enhance AAV gene therapy development through an integrated sequencing and data analysis solution. The overall Fiscal 2025 reported revenue was $593.82 million, with a reported loss of -$59.50 million.

Finance: draft 13-week cash view by Friday.

Azenta, Inc. (AZTA) - Canvas Business Model: Customer Segments

You're looking at the customer base for Azenta, Inc. as of late 2025, which is entirely focused on life sciences, having completed the strategic pivot away from semiconductor automation. The company's total revenue for the fiscal year ending September 30, 2025, reached $593.82M, with an organic growth rate of 3% for that full year. This revenue supports a global customer base, as 39% of total revenue was generated outside the United States in fiscal year 2025.

Azenta, Inc. serves its customers through two primary reporting segments: Sample Management Solutions (SMS) and Multiomics. These segments map directly to the essential needs of drug developers, researchers, and healthcare providers.

The Sample Management Solutions segment is the backbone for customers needing secure, long-term sample integrity. For instance, in the third quarter of fiscal year 2025, this segment generated $78 million in revenue, driven by services like Sample Repository Solutions and Core Products. In the fourth quarter, SMS revenue was $86 million, showing strength in areas like Clinical Biostores and Sample Storage, even with softness in Cryogenic Stores due to customer capital expenditure delays.

The Multiomics segment is the growth engine, focused on genomic services essential for modern therapy development. In the third quarter of fiscal year 2025, Multiomics revenue was $66 million, up 4% year-over-year, primarily fueled by Next Generation Sequencing. This segment directly supports advanced cell and gene therapy developers and large biotech firms needing high-throughput analysis.

Here's a quick look at the segment revenue performance from the third quarter of fiscal 2025, which gives you a clear picture of where the business was at that point:

Segment	Revenue (Q3 FY2025, in millions USD)	Year-over-Year Organic Growth (Q3 FY2025)
Sample Management Solutions	$78	-6%
Multiomics	$66	3%
Total Revenue (Continuing Operations)	$144	-2%

The customer segments are served by specific offerings within these structures. You're looking at a customer base that relies on Azenta, Inc. for mission-critical infrastructure and analysis.

• Top pharmaceutical and biotechnology companies use both segments for drug development pipelines.
• Academic and government research institutions are key users of Multiomics for discovery research.
• Clinical research organizations (CROs) and clinical trial sponsors rely heavily on Sample Management Solutions for trial material integrity.
• Advanced cell and gene therapy developers require Multiomics for sequencing and SMS for ultra-low temperature storage.
• Healthcare institutions and biobanks globally utilize Sample Repository Services and Clinical Biostores.

For the full year 2025, the company reported a strong cash position, ending the year with $283.5 million in cash, cash equivalents, and restricted cash, plus $262.7 million in marketable securities, ensuring they can continue to support these long-term customer relationships.

The Multiomics segment saw particular momentum, with organic revenue growing 10% year-over-year in the fourth quarter of fiscal 2025, driven by Next Generation Sequencing and Gene Synthesis, which are services directly tied to the most innovative drug development efforts.

Finance: draft 13-week cash view by Friday.

Azenta, Inc. (AZTA) - Canvas Business Model: Cost Structure

You're looking at the core expenses that drive Azenta, Inc.'s operations as of late 2025, focusing on the continuing businesses after the planned divestiture of B Medical Systems. The cost structure reflects a pivot toward high-tech services in Sample Management Solutions (SMS) and Multiomics.

Cost of revenue (COGS) for consumables and instruments is a primary driver. While specific 2025 COGS for consumables and instruments isn't fully itemized separately from the continuing operations' gross margin, we can infer the cost base from recent performance. For the third quarter of fiscal 2025, continuing operations generated revenue of $144 million, with an Adjusted Gross Margin of 48.5%. This implies an Adjusted Cost of Revenue of approximately $74.16 million for that quarter, which covers the direct costs associated with providing sample management products, consumables, and multiomics sequencing services. For context, the Total Cost of Revenue for the full fiscal year 2024 was $393 million on $656 million in total revenue, before the B Medical segment was classified as discontinued. The focus on higher-margin services within SMS and Multiomics is intended to improve this ratio.

Significant R&D investment for automation and multiomics expansion is managed with discipline. In the third quarter of fiscal 2025, Research and Development costs were lower year-over-year, contributing to a 6% decrease in total GAAP Operating Expenses compared to the prior year period. On a Non-GAAP basis for Q3 2025, Adjusted Operating Expense was $62 million, down 4% year-over-year, driven in part by lower R&D costs. This suggests a near-term focus on operational efficiency while maintaining necessary investment in automation for their Sample Management Solutions, such as automated stores and cryogenic systems, and expansion in Multiomics capabilities like Next Generation Sequencing.

Selling, General, and Administrative (SG&A) expenses for global sales are being tightly controlled as part of the transformation program. For Q3 2025, lower Selling, General, and Administrative expenses were a key factor in reducing the Adjusted Operating Expense to $62 million, down from $69 million in Q2 2025. This reduction in SG&A helped drive the Adjusted Operating Margin for Q3 2025 to 5.5% for continuing operations. The global sales force supports the Sample Management Solutions and Multiomics segments across North America, Europe, and Asia.

Operating costs for global biorepository and cold-chain infrastructure are embedded within COGS and operating expenses, reflecting the complexity of maintaining reliable cold-chain custody. The Sample Management Solutions segment revenue, which includes these services, was $78 million in Q3 2025. The company's commitment to this infrastructure is a fixed cost component that underpins the value proposition of sample integrity. Capital expenditures for the full fiscal year 2024 were approximately $38 million, indicating ongoing investment in these physical assets.

Restructuring and portfolio simplification costs (e.g., B Medical sale) have been a notable, though temporary, cost factor. The intention to sell the B Medical Systems segment was announced in fiscal Q1 2025, leading to its classification as a discontinued operation. In Q2 2025, the company noted increased restructuring and transformation charges. However, by Q3 2025, GAAP Operating Expenses reflected lower restructuring charges year-over-year. These charges are adjustments not representative of normal operations, but they impacted the GAAP results, contributing to the total diluted EPS loss of ($0.88) in Q2 2025, which included ($0.49) from discontinued operations.

Here's a quick look at the latest reported operational expense snapshot for continuing operations (Q3 2025):

Metric (Continuing Operations)	Q3 2025 (USD Millions)	Change vs. Q2 2025	Change vs. Q3 2024
Revenue	144	0%	0%
Adjusted Operating Expense	62	Down 10.1%	Down 4%
Adjusted Operating Margin	5.5%	+150 basis points	+340 basis points

The overall financial impact of the 2025 fiscal year, ending September 30, 2025, showed a total Net Loss attributable to common shareholders of -$59.50 million, which was a significant improvement from the -$164 million loss in fiscal year 2024. This reflects the cost discipline applied across the core business as the divestiture process moved forward.

• Total FY 2025 Revenue (All Operations): $593.82 million.
• FY 2024 Total Revenue: $656.32 million.
• Cash, cash equivalents, restricted cash and marketable securities as of March 31, 2025: $540 million.
• FY 2025 Organic Revenue Growth Guidance (Reiterated): Range of 3% to 5% relative to fiscal 2024.

Finance: draft 13-week cash view by Friday.

Azenta, Inc. (AZTA) - Canvas Business Model: Revenue Streams

You're looking at how Azenta, Inc. (AZTA) converts its core life science services into actual dollars as of late 2025. It's all about the two main pillars now that they've streamlined the portfolio. Here's the quick math on where the money came from in fiscal year 2025 (FY25).

The overall picture for FY25 showed reported revenue of $594 million, marking a 4% increase year-over-year from continuing operations. This top-line performance resulted in a Non-GAAP Diluted EPS for the full fiscal year 2025 of $0.51.

The revenue streams are clearly segmented across their two primary business units. You can see the split below:

Revenue Stream Segment	FY25 Reported Revenue (in millions)	Year-over-Year Reported Growth	FY25 Non-GAAP Gross Margin
Sample Management Solutions (SMS)	$325 million	2%	49.3% (Q4'25 SMS Non-GAAP Gross Margin)
Multiomics	$269 million	6%	Not explicitly stated for full year, Q4'25 Non-GAAP Gross Margin was 46.7% (Total)

The Multiomics segment was the primary driver of the overall revenue increase for the full year, showing 6% growth, while SMS grew 2%.

Drilling down into the specifics of how these segments generate revenue, you see a mix of service contracts, product sales, and recurring consumables revenue. For the Multiomics business, the revenue streams are heavily weighted toward high-throughput genomic services:

• Multiomics services revenue: Includes gene sequencing, synthesis, and analysis.
• Next-Generation Sequencing (NGS) services showed impressive momentum, with volume rising 50% year-over-year in the fourth quarter.
• Multiomics delivered record revenue of $73 million in the fourth quarter of 2025.

The Sample Management Solutions revenue stream is more diverse, incorporating both capital equipment sales and ongoing service/consumable revenue. This is where you find the sales of automated storage systems and cryogenic freezers, alongside the critical recurring components.

Recurring revenue from Sample Repository Services (SRS) and consumables is a key component here, providing a more predictable base. Specifically, growth in Clinical Biostores, Consumables and Instruments, and Sample Storage were cited as drivers for the SMS segment in FY25. To be fair, revenue from Cryogenic Systems and Automated Stores was lower in the fourth quarter, but other core products offset that decline.

Here are the key revenue drivers within the SMS segment as reported for the fourth quarter:

• Recurring revenue from Sample Repository Services (SRS).
• Sales of consumables and instruments.
• Revenue from Clinical Biostores.
• Sales of automated storage systems and cryogenic freezers (though Cryogenic Systems revenue was lower in Q4'25).

Finance: draft 13-week cash view by Friday.